Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Active, not recruiting · Phase 1 · NCT01955499
Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma
At a glance
- Research payments reported, 2025
- $3.4M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 39
About the trial
- Sponsor
- National Cancer Institute (NCI)
- Tested
- Biospecimen Collection (procedure), Bone Marrow Aspiration (procedure), Bone Marrow Biopsy (procedure), Computed Tomography (procedure), Ibrutinib (drug), Lenalidomide (drug), Magnetic Resonance Imaging (procedure), Positron Emission Tomography (procedure)
- Dates
- Started 2013-09-24; completion 2027-05-06
- Results posted
- Not yet
This phase I trial studies the side effects and best dose of lenalidomide and ibrutinib in treating patients with B-cell non-Hodgkin lymphoma that has returned (relapsed) or not responded to treatment (refractory). Lenalidomide helps shrink or slow the growth of non-Hodgkin lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide with ibrutinib may work better in treating non-Hodgkin lymphoma than giving either drug alone.
From ClinicalTrials.gov, last updated 2026-05-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3.4M in research payments for this study in 2025 (10 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Institute of Health $3.4M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.